Advanced Search

Technical Analysis for ANTH - Anthera Pharmaceutic

Grade Last Price % Change Price Change
D 0.0624 -10.86% -0.0076
ANTH closed down 10.86 percent on Monday, April 19, 2021, on 6 percent of normal volume.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical ANTH trend table...
Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Lower Bollinger Band Walk Weakness -10.86%
Outside Day Range Expansion -10.86%
Wide Bands Range Expansion -10.86%
Lower Bollinger Band Touch Weakness -10.86%
Lower Bollinger Band Walk Weakness -12.73%
Older End-of-Day Signals for ANTH ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators Basic chart:

Profile

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: California Biopharmaceutical Autoimmune Diseases Lisi Autoimmune Disease Pancreatic Eli Lilly And Company Amgen Mge Anthera Pharmaceuticals Enzyme Replacement Therapy Exocrine Pancreatic Insufficiency Hayward

Is ANTH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Feb 5 AM Best Comments on Credit Ratings of Anthem, Inc. and Its Subsidiaries Following MMM Holdings, LLC Acquisition Announcement
See more ANTH news...

Indicators

Indicator Value
52 Week High 0.189
52 Week Low 0.01
Average Volume 184,358
200-Day Moving Average 0.0414
50-Day Moving Average 0.0857
20-Day Moving Average 0.0747
10-Day Moving Average 0.0698
Average True Range 0.0184
ADX 17.03
+DI 9.8761
-DI 16.3052
Chandelier Exit (Long, 3 ATRs ) 0.0438
Chandelier Exit (Short, 3 ATRs ) 0.1067
Upper Bollinger Band 0.0893
Lower Bollinger Band 0.0601
Percent B (%b) 0.08
BandWidth 39.0897
MACD Line -0.0044
MACD Signal Line -0.0038
MACD Histogram -0.0006
Fundamentals Value
Market Cap 1.63 Million
Num Shares 26.2 Million
EPS -1.76
Price-to-Earnings (P/E) Ratio -0.04
Price-to-Sales 0.00
Price-to-Book 0.11
PEG Ratio -0.05
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0842
Resistance 3 (R3) 0.0843 0.0771 0.0805
Resistance 2 (R2) 0.0771 0.0716 0.0771 0.0793
Resistance 1 (R1) 0.0698 0.0682 0.0662 0.0697 0.0781
Pivot Point 0.0626 0.0626 0.0609 0.0626 0.0626
Support 1 (S1) 0.0553 0.0571 0.0517 0.0552 0.0467
Support 2 (S2) 0.0481 0.0537 0.0481 0.0455
Support 3 (S3) 0.0408 0.0481 0.0443
Support 4 (S4) 0.0407